Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA.

Neurol Clin. 2008 Aug;26(3):675-97, viii. doi: 10.1016/j.ncl.2008.03.011. Review.

2.

Review: The neurobiology of varicella zoster virus infection.

Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ.

Neuropathol Appl Neurobiol. 2011 Aug;37(5):441-63. doi: 10.1111/j.1365-2990.2011.01167.x. Review.

3.

The variegate neurological manifestations of varicella zoster virus infection.

Gilden D, Nagel MA, Cohrs RJ, Mahalingam R.

Curr Neurol Neurosci Rep. 2013 Sep;13(9):374. doi: 10.1007/s11910-013-0374-z. Review.

4.

Varicella zoster virus latency, neurological disease and experimental models: an update.

Cohrs RJ, Gilden DH, Mahalingam R.

Front Biosci. 2004 Jan 1;9:751-62. Review.

PMID:
14766405
5.

Clinical and molecular pathogenesis of varicella virus infection.

Gilden DH, Cohrs RJ, Mahalingam R.

Viral Immunol. 2003;16(3):243-58. Review.

PMID:
14583142
6.

Varicella virus-mononuclear cell interaction.

White TM, Gilden DH.

Adv Virus Res. 2003;62:1-17. Review.

PMID:
14719363
7.

The protean neurologic manifestations of varicella-zoster virus infection.

Nagel MA, Gilden DH.

Cleve Clin J Med. 2007 Jul;74(7):489-94, 496, 498-9 passim. Review.

PMID:
17682626
8.

Varicella zoster virus: natural history and current therapies of varicella and herpes zoster.

Breuer J, Whitley R.

Herpes. 2007 Sep;14 Suppl 2:25-9. Erratum in: Herpes. 2007 Dec;14(3):74.

PMID:
17939892
9.

Varicella Zoster Virus in the Nervous System.

Gilden D, Nagel M, Cohrs R, Mahalingam R, Baird N.

F1000Res. 2015 Nov 26;4. pii: F1000 Faculty Rev-1356. doi: 10.12688/f1000research.7153.1. eCollection 2015. Review.

10.

Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV).

Kennedy PG.

Neurotherapeutics. 2016 Jul;13(3):509-13. doi: 10.1007/s13311-016-0430-x. Review.

11.

Neurological complications of varicella zoster virus reactivation.

Nagel MA, Gilden D.

Curr Opin Neurol. 2014 Jun;27(3):356-60. doi: 10.1097/WCO.0000000000000092. Review.

12.

Varicella-zoster virus human ganglionic latency: a current summary.

Kennedy PG, Cohrs RJ.

J Neurovirol. 2010 Nov;16(6):411-8. doi: 10.3109/13550284.2010.515652. Epub 2010 Sep 27. Review.

PMID:
20874010
13.

Clinicopathologic understanding and control of varicella-zoster virus infection.

Asano Y.

Vaccine. 2008 Nov 25;26(50):6487-90. doi: 10.1016/j.vaccine.2008.08.004. Epub 2008 Aug 9. Review.

PMID:
18694794
14.

The global epidemiology of herpes zoster.

Yawn BP, Gilden D.

Neurology. 2013 Sep 3;81(10):928-30. doi: 10.1212/WNL.0b013e3182a3516e. Review.

15.

Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts.

Zerboni L, Reichelt M, Arvin A.

Curr Top Microbiol Immunol. 2010;342:255-76. doi: 10.1007/82_2009_8. Review.

PMID:
20225014
16.

Advances in the treatment of varicella-zoster virus infections.

Andrei G, Snoeck R.

Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. Review.

PMID:
23886000
17.
18.

Molecular and therapeutic aspects of varicella-zoster virus infection.

Quinlivan M, Breuer J.

Expert Rev Mol Med. 2005 Aug 10;7(15):1-24. Review.

PMID:
16098235
19.

Immune evasion as a pathogenic mechanism of varicella zoster virus.

Abendroth A, Arvin AM.

Semin Immunol. 2001 Feb;13(1):27-39. Review.

PMID:
11289797
20.

Varicella-zoster virus latency in human ganglia.

Kennedy PG.

Rev Med Virol. 2002 Sep-Oct;12(5):327-34. Review.

PMID:
12211045

Supplemental Content

Support Center